Santhera Pharmaceuticals Holding (0QN1) Price & Analysis

Compare

3 Followers

0QN1 Stock Chart & Stats

Day’s Range― - ―

52-Week RangeCHF7.70 - CHF17.54

Previous CloseN/A

Volume702.00

Average Volume (3M)1.92K

Market Cap

CHF119.24M

Enterprise ValueN/A

Total Cash (Recent Filing)CHF40.92M

Total Debt (Recent Filing)CHF40.62M

Price to Earnings (P/E)2.5

Beta0.34

Next Earnings

Sep 10, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.09

Shares Outstanding13,514,252

10 Day Avg. Volume2,756

30 Day Avg. Volume1,918

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)5.54

Price to Sales (P/S)0.00

P/FCF Ratio-4.85

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF30.00

Price Target Upside147.13% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Santhera Pharmaceuticals Holding News

PremiumThe Fly

Santhera price target raised to CHF 30 from CHF 25 at H.C. Wainwright

20h ago

PremiumRatings

Santhera Pharmaceuticals: Buy Rating Affirmed on Strong Commercial Traction and Promising Financial Outlook

20h ago

PremiumCompany Announcements

Santhera Pharmaceuticals: Transformative Year with AGAMREE Success

20d ago

PremiumRatings

Santhera Pharmaceuticals: Buy Rating Affirmed on Strategic Milestones and Growth Prospects

3M ago

PremiumThe Fly

Santhera price target lowered to CHF 25 from CHF 30 at H.C. Wainwright

8M ago

PremiumThe Fly

Santhera price target raised to CHF 28 from CHF 24 at H.C. Wainwright

2y ago

See All GB:0QN1 News

See All News >

Bulls Say, Bears Say

Bulls Say

Market ExpansionVamorolone commercialization continues to advance with submission to Canadian authorities expected soon and ongoing health technology assessments across key European markets.

Regulatory ApprovalThe German reimbursement agreement for AGAMREE (vamorolone) makes it the first product to receive an agreed federal price in Germany for the treatment of Duchenne muscular dystrophy.

Strategic PartnershipsA supply and distribution agreement with Clinigen Group allows Santhera to access additional markets where the product cannot be commercially obtained via current partners, optimizing the value of vamorolone.

Bears Say

Financial ExpectationsInvestors should be aware that the €52K reimbursement level in Germany exceeds original expectations for European reimbursement, initially projected at only €40K per patient.

Market CompetitionDespite the Hong Kong approval adding to a series of vamorolone approvals, competitive pressures in the Asia-Pacific region could pose challenges.

Regulatory ChallengesWhile the Scottish Medicines Consortium has recommended AGAMREE for use within NHS Scotland, navigating various national processes for health technology assessments and pricing negotiations in Europe remains complex.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

0.06%

Mutual Funds

― Other Institutional Investors

99.46% Public Companies and

Individual Investors

Detailed Ownership Overview >

0QN1 FAQ

What was Santhera Pharmaceuticals Holding Ag’s price range in the past 12 months?

Santhera Pharmaceuticals Holding Ag lowest share price was CHF7.70 and its highest was CHF17.54 in the past 12 months.

What is Santhera Pharmaceuticals Holding Ag’s market cap?

Santhera Pharmaceuticals Holding Ag’s market cap is CHF119.24M.

When is Santhera Pharmaceuticals Holding Ag’s upcoming earnings report date?

Santhera Pharmaceuticals Holding Ag’s upcoming earnings report date is Sep 10, 2025 which is in 105 days.

How were Santhera Pharmaceuticals Holding Ag’s earnings last quarter?

Santhera Pharmaceuticals Holding Ag released its earnings results on Apr 29, 2025. The company reported -CHF2.09 earnings per share for the quarter, missing the consensus estimate of -CHF0.74 by -CHF1.35.

Is Santhera Pharmaceuticals Holding Ag overvalued?

According to Wall Street analysts Santhera Pharmaceuticals Holding Ag’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Santhera Pharmaceuticals Holding Ag pay dividends?

Santhera Pharmaceuticals Holding Ag does not currently pay dividends.

What is Santhera Pharmaceuticals Holding Ag’s EPS estimate?

Santhera Pharmaceuticals Holding Ag’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Santhera Pharmaceuticals Holding Ag have?

Santhera Pharmaceuticals Holding Ag has 13,514,252 shares outstanding.

What happened to Santhera Pharmaceuticals Holding Ag’s price movement after its last earnings report?

Santhera Pharmaceuticals Holding Ag reported an EPS of -CHF2.09 in its last earnings report, missing expectations of -CHF0.74. Following the earnings report the stock price went down -2.918%.

Which hedge fund is a major shareholder of Santhera Pharmaceuticals Holding Ag?

Currently, no hedge funds are holding shares in GB:0QN1

Company Description

Santhera Pharmaceuticals Holding Ag

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

0QN1 Company Deck

0QN1 Earnings Call

Q4 2025

0:00 / 0:00

0QN1 Stock 12 Month Forecast

Average Price Target

CHF30.00

▲( 147.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"CHF6","19":"CHF19","32":"CHF32","12.5":"CHF12.5","25.5":"CHF25.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.001377216,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.001377216,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.001377216,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,12.5,19,25.5,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2022","6":"Dec<br/>2023","9":"Sep<br/>2024","12":"Feb<br/>2025","25":"Feb<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.1,18.092413632000003,19.084827264,20.077240896000003,21.069654528,22.062068160000003,23.054481792,24.046895424000002,25.039309056,26.031722688000002,27.024136320000004,28.016549952000002,29.008963584,{"y":30.001377216,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.1,18.092413632000003,19.084827264,20.077240896000003,21.069654528,22.062068160000003,23.054481792,24.046895424000002,25.039309056,26.031722688000002,27.024136320000004,28.016549952000002,29.008963584,{"y":30.001377216,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.1,18.092413632000003,19.084827264,20.077240896000003,21.069654528,22.062068160000003,23.054481792,24.046895424000002,25.039309056,26.031722688000002,27.024136320000004,28.016549952000002,29.008963584,{"y":30.001377216,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28,"date":1619827200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":31.409,"date":1622505600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.616,"date":1648771200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.599,"date":1656633600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.205,"date":1688169600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.94,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.213,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.809,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.4,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.05,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.16,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.1,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.1,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >